TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody
HEFEI, China, Dec. 17, 2022 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (Hefei, China), an innovative biotech company dedicated to the discovery of novel immunotherapeutic drugs and a leader in NK cell research globally, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TGI-2/NM1F, a novel anti-PVRIG therapeutic antibody used...
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform Cancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and more Expects ACT to contribute US$25-30 million...
Possible Breakthrough in Cardiovascular Disease Diagnostics for the United States
SINGAPORE, Dec. 16, 2022 /PRNewswire/ -- Neuome Peptides Pte. Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers. The company successfully designed specific peptides to bind to pre-established, proven biomarkers for Cardiovascular Diseases and...
Possible Breakthrough in Cardiovascular Disease Diagnostics for Southeast Asia
SINGAPORE, Dec. 16, 2022 /PRNewswire/ -- Neuome Peptides Pte. Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers. The company successfully designed specific peptides to bind to pre-established, proven biomarkers for Cardiovascular Diseases and...
CES 2023: OMRON Healthcare Introducing Initiatives to Advance Its Vision of “Going for Zero” — Elimination of Heart Attack and Stroke
KYOTO, Japan, Dec. 16, 2022 /PRNewswire/ -- OMRON Healthcare Co., Ltd. (hereinafter the Company) will exhibit at CES 2023 (*), the world's largest consumer tech show taking place in Las Vegas from Thursday, January 5, through Sunday, January 8. At the show, the Company will showcase the innovative medical devices and digital services that have been introduced over...
Novavax Announces Pricing of $65 Million Public Offering of Common Stock
GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of...
Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes
GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the "notes"). The notes are...
Digital Mental Health Company, ThoughtFull, Partners with FWD to Provide Science-Backed and Technology-Enabled Mental Health Solutions for Customers in Hong Kong and Thailand
SINGAPORE, Dec. 16, 2022 /PRNewswire/ -- Asia's leading digital mental health company, ThoughtFull, continues to bring greater accessibility of its mental wellness solutions to corporate and consumer clients across the Asia region. Today, the firm announces that it is partnering with the FWD Group Holdings Limited ("FWD Group") to launch the Mind...
Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer
HANGZHOU, China, Dec. 16, 2022 /PRNewswire/ -- Hangzhou, Zhejiang, China, , Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA),...
WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department’s Unverified List
SHANGHAI, Dec. 16, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective Dec. 16, 2022. Consequently, both subsidiaries WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai) Co.,...
